Big pharma interest remains, but the mood is fast turning gloomy.
ApexOnco Front Page
Recent articles
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Pelabresib’s Manifest-2 trial yields mixed data, but the bad part could render the whole unpalatable.
A prostate cancer project licensed from Orion enters phase 3, while pivotal trials are expanded with assets originated at Kelun and Arqule.
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
Novartis and Gracell place further bets on shortened production times, with Bristol waiting in the wings.
The new deal comes as Carvykti manufacturing problems continue and 2seventy dials down Abecma expectations.
First-in-human clinical trial initiations include yet another KRAS G12C inhibitor, and an ADC against PD-L1.